Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2013
11/19/2013US8586090 Melanin nanoshells for protection against radiation and electronic pulses
11/19/2013US8586088 Tamper-resistant oral opioid agonist formulations
11/19/2013US8586087 Temperature and pH-sensitive block copolymer having excellent gel strength
11/19/2013US8586086 Hydrogel capable of containing and conveying cells
11/19/2013US8586085 Methods and formulations for making pharmaceutical compositions containing bupropion
11/19/2013US8586084 Modified release compositions comprising tacrolimus
11/19/2013US8586083 Gastroretentive drug delivery system comprising an extruded hydratable polymer
11/19/2013US8586082 Solid orally administerable pharmaceutical dosage forms with rapid active principle release
11/19/2013US8586080 Inhibiting crystallization of steroidal hormones in transdermal delivery systems
11/19/2013US8586079 Promotional simulation for transdermal patch sampler
11/19/2013US8586078 Emulsion-containing medical articles
11/19/2013US8586076 Compositions comprising dietary fat complexer and methods for their use
11/19/2013US8586071 Bulking agents
11/19/2013US8586066 Topical antifungal composition
11/19/2013US8586064 Treating eczema and/or psoriasis
11/19/2013US8586062 Nanodispersion
11/19/2013US8586061 Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement
11/19/2013US8586060 Cosmetic or pharmaceutical preparation
11/19/2013US8586008 Pharmaceutical foam
11/19/2013US8586007 Co-polymer stabilizers for hydrofluoroalkane dispersions
11/19/2013US8585684 Reaction device controlled by magnetic control signal
11/19/2013US8584670 Method, composition, and system to control pH in pulmonary tissue of a subject
11/19/2013CA2722050C Polymerized micelles
11/19/2013CA2678956C Method of determining the weight of the coating to be applied to form a controlled release dosage form
11/19/2013CA2634073C Compositions comprising ingenol-3-angelate
11/19/2013CA2633924C Gastric reflux resistant dosage forms
11/19/2013CA2624838C Retard formulation for pralnacasan
11/19/2013CA2608629C Orally disintegrating powder comprising cilostazol and mannitol
11/19/2013CA2602750C Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide
11/19/2013CA2595043C Use of oxycodone for treating visceral pain
11/19/2013CA2572380C Gemcitabine derivatives nanoparticles
11/19/2013CA2565067C Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision
11/14/2013WO2013170195A1 Biocompatible hydrogel treatments for retinal detachment
11/14/2013WO2013170071A1 Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations
11/14/2013WO2013170012A2 Proliposomal testosterone formulations
11/14/2013WO2013169999A2 Enhanced nuclear spin polarization
11/14/2013WO2013169979A2 Polymorph compositions, methods of making, and uses thereof
11/14/2013WO2013169925A1 Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
11/14/2013WO2013169879A1 Coated medical devices comprising a water - insoluble therapeutic agent and an additive
11/14/2013WO2013169797A1 Compositions of statins and omega-3 fatty acids
11/14/2013WO2013169739A1 Novel compositions and uses of anti-hypertension agents for cancer therapy
11/14/2013WO2013169724A1 Implantable medical devices comprising a water - insoluble therapeutic agent and xylitol, iodine or edta
11/14/2013WO2013169577A1 Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
11/14/2013WO2013169523A1 Solubility enhanced compositions
11/14/2013WO2013169520A1 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
11/14/2013WO2013169458A1 Pharmaceutical compositions and methods for treating, controlling, ameliorating, or reversing conditions of dry eye
11/14/2013WO2013169406A1 Manufacturing and packaging room temperature stable dronabinol capsules
11/14/2013WO2013169218A1 Pharmaceutical compositions of s-etodolac
11/14/2013WO2013169101A1 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
11/14/2013WO2013169082A1 Bosentan controlled release oral preparation
11/14/2013WO2013169007A1 Sustained-release complex preparations for treating diabetes with improved drug compliance and method for preparing same
11/14/2013WO2013168858A1 Capsule composition containing inorganic nanoparticles for uv protection using of hydrogel-forming polymers, and method for preparing same
11/14/2013WO2013168852A1 Micro robot for in vivo drug delivery, apparatus for controlling same and drug delivery method using same
11/14/2013WO2013168627A1 CRYSTALS OF 5'-O-α-D-GLUCOPYRANOSYLADENOSINE HYDROCHLORIDE AND USE THEREOF
11/14/2013WO2013168437A1 Organic compound nanopowder, production method therefor, and suspension
11/14/2013WO2013168174A1 Apoe4 antibodies for treatment of neurodegenerative conditions
11/14/2013WO2013168172A1 Depot formulations of a local anesthetic and methods for preparation thereof
11/14/2013WO2013168167A1 Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
11/14/2013WO2013168131A1 Intrathecal administration of mtor inhibitors for the therapy of neurodegenerative, neuroinflammatory and neurooncologic diseases
11/14/2013WO2013168011A1 Compositions and methods for the treatment of chronic pain
11/14/2013WO2013168003A1 Compositions and methods for the treatment of inflammation
11/14/2013WO2013168002A1 Compositions and methods for the treatment of neurological conditions
11/14/2013WO2013168001A1 Compositions and methods for the treatment of moderate to severe pain
11/14/2013WO2013168000A1 Compositions and methods for the treatment of severe pain
11/14/2013WO2013167992A1 Compositions and methods for the treatment of inflammatory disorders
11/14/2013WO2013167988A1 Compositions and methods for the treatment of cough
11/14/2013WO2013167959A1 Myrrh based composition for otological use
11/14/2013WO2013167865A1 Pharmaceutical composition
11/14/2013WO2013167782A1 Amphiphilic copolymers carrying alpha-tocopherol having antitumoural properties
11/14/2013WO2013167742A1 Rapidly disintegrating monolayer film and use thereof in oral hygiene
11/14/2013WO2013167741A1 Sodium thiosulphate for the treatment of ectopic calcifications
11/14/2013WO2013167737A1 Pharmaceutical composition for the treatment of duchenne muscular dystrophy
11/14/2013WO2013167657A1 Parenteral esmolol formulation
11/14/2013WO2013167632A1 Ophthalmic viscoelastic device
11/14/2013WO2013167583A1 Pharmaceutical composition of a papillomavirus inhibitor
11/14/2013WO2013167453A1 Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
11/14/2013WO2013167233A1 Tobramycin formulation
11/14/2013WO2013167112A1 Composition for nasal application
11/14/2013WO2013166681A1 Composition for producing microcapsules and medicine made thereof
11/14/2013WO2013166566A1 Biodegradable three-dimensional polymer material, and method for preparing a biodegradable three-dimensional polymer material
11/14/2013WO2013133543A9 Calcium carrier, and chelated calcium pha granule and microorganism comprising same
11/14/2013WO2013129977A3 Pharmaceutical composition for injections having neuroprotector, antiamnaesic, antioxidant, antihypoxic and antiischaemic activity (embodiments)
11/14/2013WO2013107839A3 Phospholipid compounds for use in skin cancer treatment
11/14/2013WO2013085422A3 Antitubercular composition and method for producing same
11/14/2013WO2013057144A3 Aqueous dispersion having a content of lipid nanoparticles, process for production thereof and use thereof
11/14/2013WO2012136369A8 Ophthalmic preparations based on pacap (pituitary adenylate cyclase activating polypeptide) which restore the normal visual function in early glaucoma
11/14/2013US20130304167 Heat Patch for Pain
11/14/2013US20130303632 Controlled release solid dose form
11/14/2013US20130303624 Ophthalmic composition comprising geranylgeranylacetone
11/14/2013US20130303615 Antimicrobial compositions and methods
11/14/2013US20130303612 Solid dosage form comprising a fibrate
11/14/2013US20130303557 Pharmaceutical compositions and methods of treating dry eye disorders
11/14/2013US20130303501 Pharmaceutical composition and method for treating hypogonadism
11/14/2013US20130303494 Pharmaceutical Formulation Containing Gelling Agent
11/14/2013US20130303485 Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease
11/14/2013US20130303475 Tobramycin formulation
11/14/2013US20130303473 Liquid pharmaceutical composition for the treatment of a posterior eye disease
11/14/2013US20130303453 Octreotide injection
11/14/2013US20130303445 Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
11/14/2013US20130302514 Production method for adhesive patch
1 ... 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 ... 2991